Global Reperfusion Treatment Market, by Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulphide Treatment, and Others), by Injury Type (Heart Injury, Kidney Injury, Intestine Injury, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,293.6 million in 2020 and is projected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).
Global Reperfusion Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID–19 pandemic is expected to hamper the global reperfusion treatment market growth during the forecast period. The number of COVID-19 cases are increasing at an exponential rate, globally. For instance, according to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 34.8 million cases and 1 million deaths due to coronavirus disease (COVID-19) were reported on October 04, 2020 across the globe.
The COVID-19 pandemic has drastically affected the clinical trials for testing the safety and efficacy of the drugs for reperfusion therapy. According to a survey conducted by Medidata Solutions, Inc. (a U.S.-based technology company which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents had postponed their studies. The coronavirus pandemic has negatively impacted the development, production, and supply of medicines for various diseases and also affected growth of pharmaceutical businesses of various companies across the globe. The COVID-19 pandemic has affected the economy in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets.
Increasing prevalence of kidney disorders globally is expected to boost the growth of the global reperfusion treatment market during the forecast period. For instance, according to an article published in the Kidney International Journal, in 2015, delayed graft function (DGF) is a common complication that is observed in patients who had kidney transplants. According to the same source, DGF incidence ranges from 20% to 50% when the kidney is transplanted from a deceased donor, while there are around 4% to 10% incidence from kidney of a living donor.
Moreover, the increasing incidence of chronic mesenteric ischemia (CMI) is also expected to spur the growth of the global market. For instance, according to the National Center for Biotechnology Information (NCBI), 2020, around 10% of the global population over the age of 65 years is suffering from chronic mesenteric ischemia (CMI) a peripheral vascular disease. CMI is predominantly observed in females than males and mostly in the age group of 50-70 years.
Market players are focused on inorganic strategies such as acquisitions and collaborations to expand their product portfolio and strengthen their position in the global reperfusion treatment market, which in turn, is expected to drive growth of market during the forecast period. For instance, on February 12, 2020, Revive Therapeutics Ltd. acquired Psilocin Pharma Corp., a company focusing on psychedelic sciences to develop psilocybin-based therapeutics for rare diseases.
Browse 37 Market Data Tables and 25 Figures spread through 144 Pages and in-depth TOC on Global Reperfusion Treatment Market, by Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulphide Treatment, and Others), by Injury Type (Heart Injury, Kidney Injury, Intestine Injury, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), - Global Forecast to 2027.
To know the latest trends and insights prevalent in the reperfusion treatment market, click the link below:
Market players are focusing on conducting clinical trials for lead product candidate molecules in order to test the safety and effectiveness of the product. For instance, in 2015, Stealth BioTherapeutics Inc. conducted clinical trials to study the safety and efficacy of its lead product candidate, Bendavia (MTP-131) in reducing the reperfusion injury in patients with acute coronary syndrome (ACS). The clinical trial showed positive results for Bendavia (MTP-131) which can be used for managing the reperfusion injury with ACS.
Key Takeaways of the Global Reperfusion Treatment Market: